References
- Balar, A. V. (2017). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet, 389, 67–76.10.1016/S0140-6736(16)32455-2
- Balar, A. V. (2017). First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. Lancet Oncol., 18, 1483–1492.10.1016/S1470-2045(17)30616-2
- Beer, T. M. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl. J. Med., 371, 424–43310.1056/NEJMoa1405095441893124881730
- Bellmunt, J. (2017). Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New Engl. J. Med., 376, 1015–1026.10.1056/NEJMoa1613683563542428212060
- Bellmunt, J. (2009). Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. Off. J. Amer. Soc. Clin. Oncol., 27, 4454–4461.10.1200/JCO.2008.20.553419687335
- Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., Freeman, G. J. (2007). Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity, 27 (1), 111–122.10.1016/j.immuni.2007.05.016270794417629517
- Calopedos, R. J. S., Chalasani, V., Asher, R., Emmett, L., Woo, H. H. (2017). Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis., 20, 352–360.10.1038/pcan.2017.2328440324
- Cameron, F., Whiteside, G., Perry, C. (2011). Ipilimumab: First global approval. Drugs, 71 (8), 1093–1104.10.2165/11594010-000000000-0000021668044
- Chi, K. N. (2019). Apalutamide for metastatic, castration-sensitive prostate cancer. New Engl. J. Med., 381, 13–24.10.1056/NEJMoa190330731150574
- Davis, I. D. (2019). Enzalutamide with standard first-line therapy in meta-static prostate cancer. New Engl. J. Med., 381, 121–131.10.1056/NEJMoa190383531157964
- Devlin, H. (2018). James P Allison and Tasuku Honjo win Nobel prize for medicine. The Guardian. https://www.theguardian.com/science/2018/oct/01/james-p-allison-and-tasuku-honjo-win-nobel-prize-for-medicine (accessed 25.04.2021).
- Eisenberger, M. (2017). Phase III study comparing a reduced dose of cabazitaxel (20 mg/m(2)) and the currently approved dose (25 mg/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J. Clin. Oncol. Off. J. Amer. Soc. Clin. Oncol., 35, 3198–3206.10.1200/JCO.2016.72.1076
- Eisenhardt, A., Ohlmann, C. H., Doehn, C. (2020). Algorithmen zur Systemtherapie bei Prostata-, Urothel- und Nierenzellkarzinom. Der Urologe, 59, 533–543 (in German).10.1007/s00120-020-01182-0
- Falkmer, U., Jarhult, J., Wersall, P., Cavallin-Stahl, E. (2003). A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol., 42 (5–6), 620–633.10.1080/02841860310014895
- Filipovic, A., Miller, G., Bolen, J. (2020). Progress toward identifying exact proxies for predicting response to immunotherapies. Front Cell Dev. Biol., 17 (8), 155.10.3389/fcell.2020.00155
- Fizazi, K. (2017). Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New Engl. J. Med., 377, 352–360.10.1056/NEJMoa1704174
- George, D. J. (2013). Metastatic castrate resistant prostate cancer management metastatic CRPC: A cross-sectional landscape of the disease and treatments. Urology, 82, http://webedcafe.com/extern/program_media/goldjournal.net/2013/prostate_cancer/figure.php?speaker=george&figure=1 (accessed 25.04.2021).
- Grance, E., Galsky, M., Arrenz, J. A., De Santis, M., Davis, I. D., De Giorgi, U. F. F., Mencinger, M., Kikuchi, E., Garcia del Muro, X., Gumus, M., Ozguroglu, M., Rezazadeh Kalebasty, A., Park., S. H., Alekseev, B. Y., Schutz, F. A. B., Li, J. R., Mecke, A., Mariathasan, S., Thastrom, A., Bamias, A. (2019). LBA14_PRIMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Ann. Oncol., 30 (5), v888–v889.
- Heidenreich, A. (2013). Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: Results from the German compassionate-use programme. Eur. Urol., 63, 977–982.10.1016/j.eururo.2012.08.058
- Hussain, M. (2018). Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. New Engl. J. Med., 378, 2465–2474.10.1056/NEJMoa1800536
- James, N. D. (2017). Abiraterone for prostate pancer not previously treated with hormone therapy. New Engl. J. Med., 377, 338–351.10.1056/NEJMoa1702900
- James, N. D. (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 387, 1163–1177.10.1016/S0140-6736(15)01037-5
- Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., Escors, D. (2011). PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol. Med., 3 (10), 581–592.10.1002/emmm.201100165319112021739608
- Klaassen, Z., Wallis, C. J. D. (2020). First line therapy for metastatic clear cell renal cell carcinoma. Kidney-cancer-today/118209-first-line-therapy-for-metastatic-clear-cell-rcc.html (accessed 24.04.2021).
- Ljungberg, B., Albiges, L., Bensalah, K., Bex, A., Giles, R.H., Hora, M., Kuczyk, M.A., Lam, T., Marconi, L., Merseburger, A. S., Powles, T., Staehler, M., Volpe, A. (2020). EAU Guidelines on Renal Cell Carcinoma. https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Renal-Cell-Carcinoma-2020.pdf (accessed 24.04.2021).
- Maase, H. (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. Off. J. Amer. Soc. Clin. Oncol., 23, 4602–4608.10.1200/JCO.2005.07.757
- Mottet, N., Cornford, P., van den Bergh, R. C. N., De Santis, M., Fanti, S., Gillessen, S., Grummet, J., Henry, A. M., Lam, T. B., Mason, M. D., van der Kwast, T. H., van der Poel, H. G., Rouviere, O., Schoots, I. G., Tilki, D., Wiegel, T. (2020) Oncology Guidelines on Prostate Cancer. https://uroweb.org/guideline/prostate-cancer/ (accessed 24.04.2021).
- Nair, B., Wilt, T., MacDonald, R., Rutks, I. (2002). Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst. Rev., (1), CD003506.
- Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer. 12 (4), 252–264.10.1038/nrc3239
- Ryan, C. J. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol., 16, 152–160.10.1016/S1470-2045(14)71205-7
- Sharma, P. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol., 18, 312–322.10.1016/S1470-2045(17)30065-7
- Smith, M. R. (2018). Apalutamide treatment and metastasis-free survival in prostate cancer. New Engl. J. Med., 378, 1408–1418.10.1056/NEJMoa1715546
- Sweeney, C. J. (2015). Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New Engl. J. Med., 373, 737–746.10.1056/NEJMoa1503747
- Syn, N. L., Teng, M. W. L., Mok, T. S. K. Soo, R. A. (2017). De-novo and acquired resistance to immune checkpoint targeting. The Lancet Oncology, 18 (12), e731–e741.10.1016/S1470-2045(17)30607-1
- Witjes, J. A., Bruins, H. M., Cathomas, R., Comperat, E., Cowan, N. C., Gakis, G., Hernandez, V., Lorch, A., Ribal, M. J., Thalmann, G. N., van der Heijden, A. G., Veskimae, E. (2020). EAU Guidelines on muscle-invasive and metastatic bladder cancer. https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/ (accessed 24.04.2021).